SCHEMBL6540476

SCHEMBL6540476

Clc1cccc(-c2ccc3c(c2)C2(CCCCC2)CN3)c1

nearest known ligand 0.59

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PGR P06401 20/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17027040 0.82 PDE7A (0.46) PGR
SCHEMBL21382173 0.75 PDE7A (0.41)
SCHEMBL6013866 0.74 PGR (1.00) PGR
SCHEMBL4101423 0.74 PGR (1.00) PGR
SCHEMBL7557572 0.73 PGR (0.55) PGR
SCHEMBL15812245 0.72 TNKS (0.50) PGR
SCHEMBL29851080 0.72 PGR (0.58) PGR
SCHEMBL7658270 0.72 PGR (0.58) PGR
SCHEMBL4167945 0.71 PGR (0.65) PGR
SCHEMBL21537943 0.70 TNKS (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1175397-B1 3,3-SUBSTITUTED INDOLINE DERIVATIVES WYETH CORP (US) 2004-08-18 EP claimed
US-20030008909-A1 3,3-substituted indoline derivatives WYETH (US) 2003-01-09 US claimed
US-6503939-B2 That are antagonists of the progesterone receptor, in a female contraceptive kit WYETH 2003-01-07 US claimed
JP-2002543157-A 2002-12-17 JP claimed
JP-2002543181-A 2002-12-17 JP claimed
EP-1175397-A1 3,3-SUBSTITUTED INDOLINE DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 2002-01-30 EP claimed
EP-1173211-A1 CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF American Home Products Corporation (US) 2002-01-23 EP claimed
WO-2000066554-A1 3,3-SUBSTITUTED INDOLINE DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO claimed
WO-2000066166-A1 CONTRACEPTIVE COMPOSITIONS CONTAINING 3,3-SUBSTITUTED INDOLINE DERIVATIVES AND USES THEREOF AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO claimed
US-6835744-B2 For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors WYETH 2004-12-28 US disclosed
US-20020035099-A1 Combination regimens using 3,3-substituted indoline derivatives AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008909-A1 3,3-substituted indoline derivatives NR3C2, PGR, HTR3C PGR 2/4885
US-20020035099-A1 Combination regimens using 3,3-substituted indoline derivatives MC2R, PRLHR, MC5R PGR 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.